127 related articles for article (PubMed ID: 16782479)
1. Thalidomide in elderly patients with multiple myeloma.
Kusumi E; Matsumura T; Yuji K; Tanaka Y; Kami M
Lancet; 2006 Jun; 367(9527):1977; author reply 1977-8. PubMed ID: 16782479
[No Abstract] [Full Text] [Related]
2. Thalidomide therapy and deep venous thrombosis in multiple myeloma.
Rajkumar SV
Mayo Clin Proc; 2005 Dec; 80(12):1549-51. PubMed ID: 16350272
[No Abstract] [Full Text] [Related]
3. Desensitization to thalidomide in a patient with multiple myeloma.
Nucera E; Schiavino D; Hohaus S; Leone G; Buonomo A; Lombardo C; Patriarca G
Clin Lymphoma Myeloma; 2008 Jun; 8(3):176-8. PubMed ID: 18650182
[TBL] [Abstract][Full Text] [Related]
4. Bradycardia during therapy for multiple myeloma with thalidomide.
Fahdi IE; Gaddam V; Saucedo JF; Kishan CV; Vyas K; Deneke MG; Razek H; Thorn B; Bissett JK; Anaissie EJ; Barlogie B; Mehta JL
Am J Cardiol; 2004 Apr; 93(8):1052-5. PubMed ID: 15081457
[TBL] [Abstract][Full Text] [Related]
5. Thromboembolism in patients on thalidomide for myeloma.
Bowcock SJ; Rassam SM; Ward SM; Turner JT; Laffan M
Hematology; 2002 Feb; 7(1):51-3. PubMed ID: 12171777
[TBL] [Abstract][Full Text] [Related]
6. Arterial and venous thrombotic complications with thalidomide in multiple myeloma.
Alkindi S; Dennison D; Pathare A
Arch Med Res; 2008 Feb; 39(2):257-8. PubMed ID: 18164975
[No Abstract] [Full Text] [Related]
7. Low-dose vs. high-dose thalidomide for advanced multiple myeloma: a prospective trial from the Intergroupe Francophone du Myélome.
Yakoub-Agha I; Mary JY; Hulin C; Doyen C; Marit G; Benboubker L; Voillat L; Moreau P; Berthou C; Stoppa AM; Maloisel F; Rodon P; Dib M; Pegourie B; Casassus P; Slama B; Damaj G; Zerbib R; Harousseau JL; Mohty M; Facon T;
Eur J Haematol; 2012 Mar; 88(3):249-59. PubMed ID: 22023551
[TBL] [Abstract][Full Text] [Related]
8. [Low-dose thalidomide in refractory and relapsing multiple myeloma].
Radocha J; Maisnar V
Vnitr Lek; 2007 Feb; 53(2):129-34. PubMed ID: 17419173
[TBL] [Abstract][Full Text] [Related]
9. Arterial thrombosis with immunomodulatory derivatives in the treatment of multiple myeloma: a single-center case series and review of the literature.
Martin MG; Vij R
Clin Lymphoma Myeloma; 2009 Aug; 9(4):320-3. PubMed ID: 19717384
[TBL] [Abstract][Full Text] [Related]
10. Extramedullary (EMP) relapse in unusual locations in multiple myeloma: Is there an association with precedent thalidomide administration and a correlation of special biological features with treatment and outcome?
Katodritou E; Gastari V; Verrou E; Hadjiaggelidou C; Varthaliti M; Georgiadou S; Laschos K; Xirou P; Yiannaki E; Constantinou N; Markala D; Zervas K
Leuk Res; 2009 Aug; 33(8):1137-40. PubMed ID: 19250676
[TBL] [Abstract][Full Text] [Related]
11. Progress in the treatment of multiple myeloma.
Kumar S
Lancet; 2006 Mar; 367(9513):791-2. PubMed ID: 16530557
[No Abstract] [Full Text] [Related]
12. Very low doses of thalidomide as single agent in relapsed/refractory multiple myeloma.
Guglielmelli T; Capella S; Saglio G
Acta Haematol; 2006; 116(1):70-1. PubMed ID: 16809894
[No Abstract] [Full Text] [Related]
13. Pneumatosis coli after thalidomide treatment.
Ueki T; Ohashi K; Matsumoto H; Nakajima H; Akiyama H; Sakamaki H
Int J Hematol; 2006 Jun; 83(5):469. PubMed ID: 16787884
[No Abstract] [Full Text] [Related]
14. Severe hypothyroidism after thalidomide treatment.
de Savary N; Lee R; Vaidya B
J R Soc Med; 2004 Sep; 97(9):443. PubMed ID: 15340031
[No Abstract] [Full Text] [Related]
15. The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma.
Baz R; Li L; Kottke-Marchant K; Srkalovic G; McGowan B; Yiannaki E; Karam MA; Faiman B; Jawde RA; Andresen S; Zeldis J; Hussein MA
Mayo Clin Proc; 2005 Dec; 80(12):1568-74. PubMed ID: 16342649
[TBL] [Abstract][Full Text] [Related]
16. A new standard of care for elderly patients with myeloma.
Palumbo A; Boccadoro M
Lancet; 2007 Oct; 370(9594):1191-2. PubMed ID: 17920906
[No Abstract] [Full Text] [Related]
17. [Lung toxicity due to thalidomide].
Díaz García B; de Pablo Gafas A; Ferreiro Alvarez MJ
Arch Bronconeumol; 2003 May; 39(5):240. PubMed ID: 12749811
[No Abstract] [Full Text] [Related]
18. Concise review - Treatment of multiple myeloma in the very elderly: How do novel agents fit in?
Kint N; Delforge M
J Geriatr Oncol; 2016 Sep; 7(5):383-9. PubMed ID: 27567255
[TBL] [Abstract][Full Text] [Related]
19. [Treatment of myeloma when high dose therapy is not possible. New drugs--alternatives for elderly patients].
Mellstedt H; Gimsing P; Waage A
Lakartidningen; 2011 Oct 19-25; 108(42):2090-4. PubMed ID: 22165535
[No Abstract] [Full Text] [Related]
20. Monotherapy with low-dose thalidomide for relapsed or refractory multiple myeloma: better response rate with earlier treatment.
Maisnar V; Radocha J; Büchler T; Bláha V; Malý J; Hájek R
Eur J Haematol; 2007 Oct; 79(4):305-9. PubMed ID: 17803678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
